|Interleukin‐8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models|
Y Ning, PC Manegold, YK Hong, W Zhang, A Pohl, G Lurje, T Winder, ...
International Journal of Cancer 128 (9), 2038-2049, 2011
|Standing the test of time: targeting thymidylate biosynthesis in cancer therapy|
PM Wilson, PV Danenberg, PG Johnston, HJ Lenz, RD Ladner
Nature reviews Clinical oncology 11 (5), 282, 2014
|Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan|
J Boyer, EG McLean, S Aroori, P Wilson, A McCulla, PD Carey, ...
Clinical cancer research 10 (6), 2158-2167, 2004
|A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal …|
W Zhang, T Winder, Y Ning, A Pohl, D Yang, M Kahn, G Lurje, MJ Labonte, ...
Annals of Oncology 22 (1), 104-109, 2011
|Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer|
J Boyer, WL Allen, EG McLean, PM Wilson, A McCulla, S Moore, ...
Cancer research 66 (5), 2765-2777, 2006
|Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer …|
G Lurje, F Nagashima, W Zhang, D Yang, HM Chang, MA Gordon, ...
Clinical Cancer Research 14 (23), 7884-7895, 2008
|Characterization of human angiogenin variants implicated in amyotrophic lateral sclerosis|
B Crabtree, N Thiyagarajan, SH Prior, P Wilson, S Iyer, T Ferns, R Shapiro, ...
Biochemistry 46 (42), 11810-11818, 2007
|Common cancer stem cell gene variants predict colon cancer recurrence|
A Gerger, W Zhang, D Yang, P Bohanes, Y Ning, T Winder, MJ LaBonte, ...
Clinical Cancer Research 17 (21), 6934-6943, 2011
|DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines|
MJ LaBonte, PM Wilson, W Fazzone, S Groshen, HJ Lenz, RD Ladner
BMC medical genomics 2 (1), 67, 2009
|The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models|
MJ LaBonte, PM Wilson, W Fazzone, J Russell, SG Louie, A El-Khoueiry, ...
Cancer research 71 (10), 3635-3648, 2011
|Molecular markers in the treatment of metastatic colorectal cancer|
PM Wilson, MJ LaBonte, HJ Lenz
The Cancer Journal 16 (3), 262-272, 2010
|Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells|
W Fazzone, PM Wilson, MJ LaBonte, HJ Lenz, RD Ladner
International Journal of Cancer 125 (2), 463-473, 2009
|Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer|
A Gerger, A El-Khoueiry, W Zhang, D Yang, H Singh, P Bohanes, Y Ning, ...
Clinical Cancer Research 17 (17), 5783-5792, 2011
|Novel opportunities for thymidylate metabolism as a therapeutic target|
PM Wilson, W Fazzone, MJ LaBonte, J Deng, N Neamati, RD Ladner
Molecular cancer therapeutics 7 (9), 3029-3037, 2008
|A novel fluorescence-based assay for the rapid detection and quantification of cellular deoxyribonucleoside triphosphates|
PM Wilson, MJ LaBonte, J Russell, S Louie, AA Ghobrial, RD Ladner
Nucleic acids research 39 (17), e112-e112, 2011
|Inhibition of dUTPase induces synthetic lethality with thymidylate synthase–targeted therapies in non–small cell lung cancer|
PM Wilson, MJ LaBonte, HJ Lenz, PC Mack, RD Ladner
Molecular cancer therapeutics 11 (3), 616-628, 2012
|Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage|
PM Wilson, W Fazzone, MJ LaBonte, HJ Lenz, RD Ladner
Nucleic acids research 37 (1), 78-95, 2009
|The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells|
WL Allen, EG McLean, J Boyer, A McCulla, PM Wilson, V Coyle, ...
Molecular cancer therapeutics 6 (1), 128-137, 2007
|Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks.|
S Senan, R Rampling, MA Graham, P Wilson, H Robin, N Eckardt, ...
Clinical cancer research 3 (1), 31-38, 1997
|Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients|
T Winder, W Zhang, D Yang, Y Ning, P Bohanes, A Gerger, PM Wilson, ...
Clinical Cancer Research 16 (22), 5591-5602, 2010